Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells $191,749.90 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,085 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total transaction of $191,749.90. Following the transaction, the insider now owns 255,348 shares of the company’s stock, valued at approximately $11,986,035.12. The trade was a 1.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.07, for a total transaction of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total value of $394,034.80.

Apogee Therapeutics Stock Performance

Shares of NASDAQ APGE opened at $47.77 on Monday. The stock has a market cap of $2.15 billion, a PE ratio of -19.74 and a beta of 2.26. The business has a fifty day moving average of $49.13 and a two-hundred day moving average of $48.75. Apogee Therapeutics, Inc. has a 52-week low of $27.05 and a 52-week high of $72.29.

Institutional Investors Weigh In On Apogee Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Point72 DIFC Ltd bought a new stake in Apogee Therapeutics during the second quarter worth about $660,000. Point72 Asset Management L.P. boosted its holdings in shares of Apogee Therapeutics by 162.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock worth $41,545,000 after acquiring an additional 438,036 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Apogee Therapeutics in the 2nd quarter worth approximately $706,000. Victory Capital Management Inc. increased its holdings in Apogee Therapeutics by 56.8% during the 2nd quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock valued at $6,149,000 after purchasing an additional 56,607 shares in the last quarter. Finally, Waypoint Capital Advisors LLC acquired a new stake in Apogee Therapeutics during the 3rd quarter valued at $36,835,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Wall Street Analysts Forecast Growth

APGE has been the subject of a number of research reports. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Wedbush boosted their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. Finally, Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics has a consensus rating of “Buy” and a consensus target price of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.